Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake

Rhea-AI Filing Summary

Myriad Genetics director Daniel Skovronsky filed a Form 4 reporting his direct holdings in the company. The filing lists ownership of 195,507 shares of Common Stock after the reported entry. The record is characterized as a holdings entry, not as a new purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Skovronsky Daniel

Role null

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 195,507 shares (Direct, null)

Footnotes (1)

Key Figures

Shares held after entry: 195,507 shares

1 metrics

Shares held after entry 195,507 shares Direct Common Stock holdings following reported Form 4 entry

Key Terms

Common Stock, Form 4, reporting person

3 terms

Common Stock financial

"security_title: Common Stock reported in the Form 4 data"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"Insider ownership reported on Form 4 for Myriad Genetics"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

reporting person regulatory

"Reporting person listed as director Daniel Skovronsky"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:25 PM Accepted by SEC EDGAR 06/23/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skovronsky Daniel

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								195,507	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This "Exit" Form 4 is voluntarily filed to report solely that the Reporting Person is no longer serving in the role as a director of the Company, effective June 17, 2026, and therefore is no longer subject to Section 16 reporting.

	By: Justin Hunter For: Daniel Skovronsky	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Myriad Genetics (MYGN) director Daniel Skovronsky report in this Form 4?

Director Daniel Skovronsky reported his current holdings of Myriad Genetics Common Stock. The Form 4 shows his direct ownership position rather than detailing a new purchase or sale, updating investors on the size of his reported stake in the company.

How many Myriad Genetics (MYGN) shares does Daniel Skovronsky hold after this Form 4?

After the reported entry, Daniel Skovronsky holds 195,507 shares of Myriad Genetics Common Stock directly. This figure reflects his ownership position as disclosed in the Form 4 and provides a snapshot of his reported stake at the time of the filing.

Does this Myriad Genetics (MYGN) Form 4 show a buy or sell by Daniel Skovronsky?

The Form 4 is recorded as a holdings entry, not a new purchase or sale. It updates Daniel Skovronsky’s reported ownership in Myriad Genetics Common Stock without specifying any transaction direction such as buying, selling, acquiring, or disposing of shares.

What type of security is reported in Daniel Skovronsky’s Myriad Genetics (MYGN) Form 4?

The Form 4 reports holdings of Myriad Genetics Common Stock. This is the company’s primary equity security and the filing indicates how many shares Daniel Skovronsky directly owns following the reported entry, helping investors understand his equity exposure.

Is Daniel Skovronsky a major shareholder of Myriad Genetics (MYGN) based on this Form 4?

The Form 4 identifies Daniel Skovronsky as a director rather than a ten percent owner. It shows he directly holds 195,507 shares of Common Stock, clarifying his role and giving investors visibility into the scale of his reported equity position in the company.